Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 1
2008 2
2009 2
2010 2
2011 1
2012 1
2013 2
2014 3
2015 4
2016 3
2017 4
2018 1
2019 2
2020 3
2021 2
2022 2
2023 3
2024 1
2025 6
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z. Stupp R, et al. Among authors: palti y. JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718. JAMA. 2017. PMID: 29260225 Free PMC article. Clinical Trial.
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z. Stupp R, et al. Among authors: palti y. JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669. JAMA. 2015. PMID: 26670971 Free article. Clinical Trial.
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.
Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbalý V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH. Stupp R, et al. Among authors: palti y. Eur J Cancer. 2012 Sep;48(14):2192-202. doi: 10.1016/j.ejca.2012.04.011. Epub 2012 May 18. Eur J Cancer. 2012. PMID: 22608262 Free article. Clinical Trial.
The transcriptomic fingerprint of cancer response to Tumor Treating Fields (TTFields).
Wainer-Katsir K, Haber A, Fishman H, Ding L, Story MD, Du R, Kahlert UD, Mannarino L, Mirimao F, Lupi M, D'Incalci M, Lavy-Shahaf G, Ene H, Frechtel-Gerzi R, Drawshy Z, Martinez-Conde A, Dor-On E, Porat Y, Giladi M, Weinberg U, Palti Y. Wainer-Katsir K, et al. Among authors: palti y. Cell Death Discov. 2025 Jul 10;11(1):319. doi: 10.1038/s41420-025-02615-5. Cell Death Discov. 2025. PMID: 40640144 Free PMC article.
Role of the PI3K/AKT signaling pathway in the cellular response to Tumor Treating Fields (TTFields).
Klein-Goldberg A, Voloshin T, Zemer Tov E, Paz R, Somri-Gannam L, Volodin A, Koren L, Lifshitz L, Meir A, Shabtay-Orbach A, Blatt R, Cahal S, Tempel-Brami C, Wainer-Katsir K, Kan T, Koltun B, Brant B, Barsheshet Y, Haber A, Giladi M, Weinberg U, Palti Y. Klein-Goldberg A, et al. Among authors: palti y. Cell Death Dis. 2025 Mar 27;16(1):210. doi: 10.1038/s41419-025-07546-8. Cell Death Dis. 2025. PMID: 40148314 Free PMC article.
Cancer Cell Permeability Induced by Tumor Treating Fields (TTFields) as a Physical Approach to Improve Chemotherapy Uptake and Overcome Multidrug Resistance.
Koltun B, Voloshin T, David C, Kan T, Barsheshet Y, Volodin A, Cahal S, Tempel-Brami C, Shai M, Jacobovitch S, Roash-Lancry D, Brant B, Kaynan N, Koren L, Klein-Goldberg A, Zemer Tov E, Paz R, Haber A, Giladi M, Weinberg U, Palti Y. Koltun B, et al. Among authors: palti y. Mol Cancer Ther. 2025 Nov 3;24(11):1815-1825. doi: 10.1158/1535-7163.MCT-25-0019. Mol Cancer Ther. 2025. PMID: 40583763 Free PMC article.
Tumor treating fields: a new frontier in cancer therapy.
Davies AM, Weinberg U, Palti Y. Davies AM, et al. Among authors: palti y. Ann N Y Acad Sci. 2013 Jul;1291:86-95. doi: 10.1111/nyas.12112. Epub 2013 May 9. Ann N Y Acad Sci. 2013. PMID: 23659608 Review.
Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo.
Davidi S, Jacobovitch S, Shteingauz A, Martinez-Conde A, Braten O, Tempel-Brami C, Zeevi E, Frechtel-Gerzi R, Ene H, Dor-On E, Voloshin T, Tzchori I, Haber A, Giladi M, Kinzel A, Weinberg U, Palti Y. Davidi S, et al. Among authors: palti y. Cancers (Basel). 2022 Jun 15;14(12):2959. doi: 10.3390/cancers14122959. Cancers (Basel). 2022. PMID: 35740624 Free PMC article.
43 results